Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials

We performed a pooled analysis to evaluate the efficacy and adverse events (AEs) of olanzapine combined with dexamethasone plus 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) compared with 5-HT3 RA plus dexamethasone for the prevention and treatment of chemotherapy-induced nausea and vomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian-Guo, Huang, Lang, Jin, Su-Han, Xu, Cheng, Frey, Benjamin, Ma, Hu, Gaipl, Udo S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046384/
https://www.ncbi.nlm.nih.gov/pubmed/32079622
http://dx.doi.org/10.1136/esmoopen-2019-000621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046384/
https://www.ncbi.nlm.nih.gov/pubmed/32079622
http://dx.doi.org/10.1136/esmoopen-2019-000621

Ejemplares similares